RecruitingEarly Phase 1NCT04398719

CBD-Microglia PET Study

Effect of Cannabidiol on Microglial Activation and Central Pain-Sensitization


Sponsor

Yale University

Enrollment

15 participants

Start Date

May 7, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to examine the effect of cannabidiol (CBD) pre-treatment on brain microglial activation in healthy human subjects. Secondarily, this study aims to examine the effect of cannabidiol (CBD) pre-treatment on central pain-sensitization in healthy human subjects.


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Inclusion Criteria5

  • Men and women aged 18- 55 years
  • No significant medical or neurological illness
  • No implanted metal devices that may pose a risk during MRI scanning
  • Within the annual permissible radiation exposure
  • Able to provide written informed consent.

Exclusion Criteria3

  • Current use of any medications
  • Presence of metal in the body
  • Pregnancy or lactation

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATION[11C]PBR28

The radiotracer, \[11C\]PBR28, will be administered at the beginning of each PET scan

DRUGLow-dose lipopolysaccharide

Subjects will receive intravenous lipopolysaccharide.

DRUGIntradermal Capsaicin

A small dose of capsaicin will be administered by intradermal injection.


Locations(1)

Connecticut Mental Health Center

New Haven, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04398719


Related Trials